Rubidium.
Trace mineral for mood. Experimental. A trace alkali metal the body handles much like potassium. No role of its own has been identified, and it appears in trace mineral blends as part of a full element spread.
Reviewed March 2026
- Category
- Mineral
- Also filed under
- MoodDepressionExperimental
What Rubidium is, and what it does.
- Does it work
- It suits people who want a trace mineral blend mirroring what plant foods and mineral waters carry. No requirement has ever been set for it.
- How much to take
- Start with 100 to 500mcg a day, the band trace blends are built on. Trials have used 1,000mcg, a research condition. No official intake figure exists for it.
- Time to feel it
- Nobody has measured a timeline for it at these amounts. Because it follows potassium into cells and is recycled by the kidney, it builds slowly across weeks.
- The first dose
- Day one it is absorbed and distributed into the same intracellular pool potassium occupies. Nothing has been measured about how a first dose registers.
- With regular use
- Most effects take 2-8 weeks. Be patient.
- How well tolerated
- Generally well tolerated. Check with your doctor if on medications.
- How it feels
- No sensation has been documented at trace amounts. Older mood research used gram scale amounts, which is a very different exposure from a microgram trace.
- The overlooked benefit
- Its potassium mimicry is genuinely useful in a laboratory: rubidium-86 has long served as a tracer for potassium flux and for tissue perfusion measurement.
100 to 500mcg a day is where Rubidium works.
Source: Fieve et al., 1973; trace mineral literature
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 3 human trials.
- Substitution for potassium at transporters and channelsIn vitro study
- Use as a tracer for potassium flux and tissue perfusionNarrative review
- Trace element intake from plant foods and mineral watersNarrative review
- Renal handling alongside potassiumAnimal study
Questions people ask about Rubidium.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Rubidium is an alkali metal that the sodium potassium pump and potassium channels move in place of potassium, so the two share the same routes into cells. Potassium status therefore governs how much rubidium is taken up and retained, which makes normal potassium intake the reference point wherever rubidium appears in a formula.
Rubidium is an alkali cation that the sodium-potassium ATPase accepts in place of potassium, so its cellular movement is set by the same pump that exchanges sodium out for potassium in. Sodium status therefore sits upstream of how rubidium distributes between plasma and cells. This is pump pharmacology, not a demonstrated nutritional benefit of taking the two together.
The sodium-potassium ATPase hydrolyses magnesium-bound ATP, so magnesium availability is a condition for the transport step that carries rubidium into cells. Low magnesium status blunts pump turnover generally rather than acting on rubidium specifically. Read this as mechanistic background rather than a clinical pairing.
Rubidium appears alongside manganese, copper and iron in mixture-exposure epidemiology, where the mixture rather than any single element is modelled. An association measured in a mixture is not a cause and does not describe what happens when the two are supplemented together. It is listed so that formulators know the pair is co-studied, nothing more.
Copper and rubidium were entered into the same mixture model in maternal exposure work, so any reported signal belongs to the combination and to the cohort design. This is an observational association in pregnancy, not a supplementation finding. No dose relationship for supplemental intake can be read from it.
Manganese was one of the four elements modelled with rubidium in the mixture analysis of pregnancy outcomes. Mixture epidemiology attributes effects to a profile of exposures rather than to a single element, and the direction for rubidium alone is not separable. Regard it as a co-occurrence flag.
Rubidium reaches consumers almost entirely as a trace constituent of ionic mineral concentrates rather than as a standalone dose, so it is normally declared inside a broader electrolyte matrix. The matrix sets the total monovalent cation load a serving delivers. This is a labelling and formulation observation rather than an interaction with an outcome attached.
Nothing specific on file for Rubidium. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Rubidium actually does.
The body moves rubidium using the same doorways it uses for potassium, because the two ions look similar to those doorways.
Researchers use a radioactive form of rubidium to watch where potassium goes, since it follows the same route.
No human requirement for rubidium has been identified. It turns up in food mostly because it travels with potassium.
The kidneys deal with rubidium roughly the way they deal with potassium, so how much potassium you take in affects how long rubidium stays around.
Where Rubidium comes from.
There is no rubidium mine. It comes out as a side stream when other minerals are processed, and the hard part is separating it from caesium, which behaves almost the same way.
From a mineral source, then refined and usually bound to a carrier so the body can take it up.
Rubidium has no ore of its own at commercial scale. It is recovered as a minor component of lithium-bearing mica and caesium minerals, and from certain brines.
The mineral is digested and the alkali metals pass into solution together, giving a mixed lithium, potassium, caesium and rubidium liquor.
Rubidium and caesium are chemically close, so separation relies on fractional crystallisation of double salts or on ion-exchange, which is the step that sets the grade.
The purified stream is converted to the chloride for a defined-content ingredient, or rubidium simply remains as a declared trace cation in a mineral concentrate that was never separated.
Getting Rubidium from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A cross-sectional analysis relating a panel of urinary metals, rubidium among them, to measures of excess body weight around the abdomen; the paper reports associations, not effects of intake.Cross-sectional study. Yao M et al., 2026 (European Journal of Medical Research). PMID 41535962 ↗
- Reports a combined association between a maternal manganese, copper, rubidium and iron exposure mixture and low iron status in pregnancy, with a mediation pathway explored; an association in a mixture model is not a cause.Cohort study. Zhong Y et al., 2025 (Ecotoxicology and Environmental Safety). PMID 40451028 ↗
- Examines prenatal metal exposures, including rubidium within the measured panel, against child neurodevelopmental scores and metabolic pathway perturbation; the design supports association and mediation modelling only.Cohort study. Xie Y et al., 2025 (Nature Communications). PMID 40025012 ↗
These are the studies our verdict leans on, chosen from the 3 we read for Rubidium. The full linked list is below.
The studies, linked.
12 sources behind our Rubidium verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- ClinicalTrials.gov ↗
- Clinical trialComparison of the Diagnostic Performances of 82Rubidium Positron Emission Tomography and Conventional Scintigraphy With CZT Cameras for Detection of Myocardial Ischemia in a Population of Overweighed Patients and WomenClinicalTrials.gov ↗NA · 313 participants · Completed
- Clinical trialA Prospective Comparison of Gated, Rest/Stress Rubidium-82 Position Emission Computed Tomography (PET) vs. Gated, Rest / Stress Technetium 99-m SPECTClinicalTrials.gov ↗136 participants · Completed
- Clinical trialCharacterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency InvestigationClinicalTrials.gov ↗PHASE4 · 80 participants · Completed
- Clinical trialPerfusion Analysis Using Rubidium in Cardiac SarcoidosisClinicalTrials.gov ↗NA · 53 participants · Completed
- Clinical trialInitial Human Validation of Simultaneous Dual-Tracer Cardiac PET ImagingClinicalTrials.gov ↗EARLY PHASE1 · 30 participants · Completed
- Clinical trialEffects of Controlled Hypercapnic Stimulation on Myocardial Blood Flow Measured With Positron Emission TomographyClinicalTrials.gov ↗NA · 20 participants · Terminated
- Clinical trialOptimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac SarcoidosisClinicalTrials.gov ↗EARLY PHASE1 · 15 participants · Completed
- Clinical trialDanish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 3ClinicalTrials.gov ↗1,000 participants · Unknown
- Clinical trialTumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic CorrelationClinicalTrials.gov ↗NA · 500 participants · Unknown
- Clinical trialComparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging: The FLARE (Flurpiridaz vs. Rubidium Evaluation) TrialClinicalTrials.gov ↗60 participants · Recruiting
- Clinical trialOptimization of Image Quality for Myocardial Perfusion Imaging With Rubidium-82 PET in Patients With Known or Suspected Ischemic Heart Disease (RUBY-DOSE)ClinicalTrials.gov ↗48 participants · Active not recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 852 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Rubidium is, not how risky it is. A report is not proof Rubidium caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.